Growth factors provide powerful mitogenic and survival signals to breast cancer cells and it is therefore not surprising that they are able to subvert inhibitory responses to anti-hormonal drugs. In this review we discuss several mechanisms by which this may be achieved and expand our observations to encompass recently emerging anti-growth factor treatments. The information presented is underpinned by inhibitor studies that show the targeting of such mechanisms in advance of anti-hormone or anti-growth factor resistance development is able to substantially delay this event, thus pointing the way forward to intelligent combination therapies relevant to the future management of breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11154-007-9033-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dihydroartemisinin inhibits tumor progress via blocking ROR1-induced STAT3-activation in non-small cell lung cancer.
Int Immunopharmacol
May 2024
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, China. Electronic address:
Article Synopsis
- Dihydroartemisinin (DHA), a derivative of artemisinin, shows promise in treating non-small cell lung cancer (NSCLC) by inhibiting tumor growth and influencing the STAT3 signaling pathway.
- The research indicates that DHA significantly lowers the levels of receptor tyrosine kinase-like orphan receptor 1 (ROR1), which interacts with and promotes the STAT3 pathway, thus contributing to anti-cancer effects.
- By blocking ROR1, DHA effectively reduces STAT3 activation, suggesting that targeting ROR1 could be a potential strategy in developing treatments for NSCLC.
YTHDF2 governs muscle size through a targeted modulation of proteostasis.
Nat Commun
March 2024
Department of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, USA.
The regulation of proteostasis is fundamental for maintenance of muscle mass and function. Activation of the TGF-β pathway drives wasting and premature aging by favoring the proteasomal degradation of structural muscle proteins. Yet, how this critical post-translational mechanism is kept in check to preserve muscle health remains unclear.
View Article and Find Full Text PDFKCTD15 acts as an anti-tumor factor in colorectal cancer cells downstream of the demethylase FTO and the m6A reader YTHDF2.
Commun Biol
March 2024
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Article Synopsis
- * Experiments show that overexpressing KCTD15 reduces CRC cell proliferation and promotes apoptosis, while its regulation is influenced by the FTO-YTHDF2 axis, which affects RNA stability.
- * KCTD15 enhances the stability of the tumor suppressor protein p53, likely through a mechanism involving histone deacetylase 1 (HDAC1), which contributes to its anti-cancer effects in CRC cells.
Disproportionality Analysis of Stomatitis Associated with Anticancer Drugs Using the Japanese Adverse Drug Event Report Database.
Oncology
September 2024
School of Pharmacy, Hyogo Medical University, Kobe, Japan.
Introduction: Anticancer drug-induced stomatitis can affect a patient's quality of life and the continuation of drug treatment. Although there have been reports of the occurrence of stomatitis associated with anticancer agents in clinical trials, few Japanese participants have been enrolled in clinical trials and have not been sufficiently investigated. In addition, there has been little attention on research on anticancer drugs associated with stomatitis by patient stratification with different carcinogenic sites.
View Article and Find Full Text PDFPrognostic Biomarkers in Pituitary Tumours: A Systematic Review.
touchREV Endocrinol
November 2023
Second Department of Surgery, Aretaieio Hospital Athens, Medical School, Athens, Greece.
Pituitary tumours (PTs) are the second most common intracranial tumour. Although the majority show benign behaviour, they may exert aggressive behaviour and can be resistant to treatment. The aim of this review is to report the recently identified biomarkers that might have possible prognostic value.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!